Log In
Print this Print this

tideglusib (AMO-02) (formerly NP-12)

Also known as: formerly Nypta, Zentylor

  Manage Alerts
Collapse Summary General Information
Company Noscira S.A.
DescriptionGlycogen dependent kinase 3 (GSK3) inhibitor
Molecular Target Glycogen dependent kinase 3 (GSK3)
Mechanism of ActionKinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMyotonic dystrophy type 1 (DM1)
Indication DetailsTreat adolescents and adults with congenital and juvenile-onset myotonic dystrophy; Treat myotonic dystrophy type 1 (DM1)
Regulatory Designation
PartnerAMO Pharma Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today